Mirati Therapeutics, 3545 Cray Court, San Diego, CA 92121, USA.
Int J Mol Sci. 2023 Apr 17;24(8):7373. doi: 10.3390/ijms24087373.
Within the MAPK/RAS pathway, there exists a plethora of protein-protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with -mutant driven cancers. In this review, we focus on recent strategies to inhibit RAS-signaling via disrupting PPIs associated with SOS1, RAF, PDEδ, Grb2, and RAS.
在 MAPK/RAS 通路中，存在大量的蛋白质-蛋白质相互作用 (PPIs)。多年来，科学家们一直致力于靶向 KRAS 及其效应物，希望为突变驱动的癌症患者提供急需的治疗方法。在这篇综述中，我们重点介绍了通过破坏与 SOS1、RAF、PDEδ、Grb2 和 RAS 相关的 PPIs 来抑制 RAS 信号的最新策略。
Zotero 插件
